FAQ on Aditxt Inc.'s Subsidiary Pearsanta's Planned IPO and Its Implications

What is the main purpose of Pearsanta’s planned IPO?

The planned IPO is intended to support the clinical validation and commercial rollout of Pearsanta’s early cancer and disease detection tests powered by its Mitomic mitochondrial DNA platform and CLIA-certified, CAP-accredited laboratory infrastructure.

Why is Pearsanta’s IPO significant?

The IPO aligns with Aditxt’s Acquire, Build, and Capitalize strategy, positioning Pearsanta to expand market access and deliver life-saving diagnostics through early detection.

Who is the lead underwriter for Pearsanta’s IPO?

Spartan Capital Securities, LLC has been engaged as the lead underwriter for Pearsanta’s planned IPO.

What technology powers Pearsanta’s early detection tests?

Pearsanta’s early detection tests are powered by its Mitomic mitochondrial DNA platform.

What is Aditxt Inc.’s focus?

Aditxt is an innovation platform dedicated to accelerating promising health innovations, currently operating programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

How does Aditxt plan to expand its health innovation programs?

Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. and a merger agreement with Evofem to introduce programs dedicated to public health and women’s health, subject to certain conditions.

Where can investors find the latest news and updates about Aditxt Inc.?

The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX.

What are the conditions for the closing of Aditxt’s transactions with Appili and Evofem?

The closing of the transactions is subject to several conditions, including approval by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.